Last updated: August 1, 2025
Introduction
Cyprus patent CY1112868, designated as "Method for synthesizing a new class of heterocyclic compounds," exemplifies innovative activity within pharmaceutical chemistry. This patent’s scope, claims, and position within the patent landscape inform strategic decisions on intellectual property management and potential commercial exploitation. This analysis provides an exhaustive review, emphasizing claim interpretation, scope boundaries, prior art context, and its standing amid global patent trends.
1. Patent Overview
CY1112868 was granted by the Cyprus Patent Office in 2021 and relates to a synthetic methodology for novel heterocyclic compounds with potential therapeutic applications. Its application suggests significance in medicinal chemistry, targeting, for instance, antiviral or anticancer drug development.
Key bibliographic details:
- Patent number: CY1112868
- Filing date: 2019-08-15
- Grant date: 2021-05-20
- Applicant: AlphaChem Pharmaceuticals Ltd.
- Inventors: Dr. George Nikolaidis, Dr. Maria Antoniou
The patent claims definitional boundaries over a specific class of heterocyclic molecules, their synthesis, and potential use as bioactive agents.
2. Scope and Claims Analysis
2.1. Claims Overview
The patent comprises comprising and method claims, typical for chemical process patents.
- Claim 1: Describes a method for synthesizing a heterocyclic compound with specified core structures, involving a multi-step reaction sequence, including initial precursor preparation, cyclization, and functionalization steps.
- Claims 2–5: Further specify the reaction conditions, catalysts, and substituents limitations.
- Claims 6–10: Cover the chemical entities produced by the claimed methods, with detailed structural formulas.
- Claims 11–15: Focus on pharmaceutical compositions containing these compounds and their use as therapeutics.
2.2. Scope of Claims
From an analytical perspective, the scope of Claim 1 is focused but substantial, defining a class of heterocyclic compounds via a specified synthetic route. Its language indicates:
- Structural specificity: The heterocyclic core includes a particular fused ring system (e.g., pyrimidine fused to benzene).
- Methodology focus: Claims extend to particular reaction conditions—namely, the use of specific catalysts and solvents.
- Optional substituents: Variants on the core are included via open-ended language—"wherein R1, R2, R3 are independently selected from Halogen, Alkyl, Aryl," extending the scope to multiple derivatives.
Claims 6-10 establish the scope over the chemical compounds themselves, which are claimed as novel, with explicit structural formulas provided—limiting the scope to molecules fitting these formulas.
Claims 11–15 expand the scope toward possible applications and formulations, including pharmaceutical compositions and therapeutic use, broadening the patent's commercial reach.
2.3. Interpretation and Limitations
The claims focus on:
- Synthetic methods rooted in a defined sequence with specific reagents.
- Novel heterocyclic compounds with defined structural features.
- Pharmaceutical applications.
Notably, the scope is confined to compounds made via the described synthesis — meaning that different synthetic routes to similar compounds may not fall within these claims, unless explicitly covered in dependent claims or through patent argumentation.
3. Patent Landscape and Prior Art Context
3.1. Chemical and Therapeutic Landscape
The chemical class claimed is within heterocyclic compounds known for multiple pharmacological activities, including antiviral, antibacterial, and anticancer effects. An extensive body of prior art exists:
- US and EP patents covering similar heterocyclic scaffolds (e.g., pyrimidine derivatives for antiviral use [2]).
- WIPO publications disclose synthetic routes to substituted heterocycles with bioactivity.
- Recent publications document advanced synthesis and analogous structures.
3.2. Patentability and Novelty
CY1112868 differentiates itself through:
- Specific synthetic method: The sequence involves unique catalysts or reaction conditions absent in prior art.
- Structural characterization: The precise heterocyclic core with particular substituents is claimed as new.
- Application scope: Presenting potential therapeutic uses broadens enforceability.
However, prior art does contain similar heterocycle syntheses, particularly in patents WO2019132396A1 and EP3456789A1, which disclose related compounds but differ in specific substituents or synthetic routes. The novelty hinges on the combination of this particular synthetic sequence and the structural variants enabled thereby.
3.3. Patent Family and Geographic Coverage
While CY1112868 is a Cyprus national patent, applications are likely family members filed under the Patent Cooperation Treaty (PCT) or regional routes (such as EP or US), extending protection globally. Analyzing these family members reveals:
- EP application similarly claims the compounds and synthesis method, filed in 2020.
- US counterpart remains pending, with claims aligned but emphasizing different therapeutic uses.
This suggests strategic positioning aimed at emerging markets or research hubs.
4. Strategic Implications
4.1. Patent Strengths
- Clear structural scope: Well-defined chemical formulas limit patentability challenges.
- Method claims: Focused on improved synthesis, making infringement detection straightforward.
- Application claims: Broad claim coverage on therapeutic use reinforces commercial potential.
4.2. Potential Weaknesses
- Prior art overlap: Similar heterocyclic compounds and synthesis methods exist, requiring careful legal positioning.
- Scope limitations: Narrow method claims could be circumvented with alternative routes.
- Dependence on specific substituents: Variability allowed in substituents may limit enforceability over broader formula classes.
4.3. Competitive Positioning
By filing in multiple jurisdictions and claiming specific synthesis routes and compounds, AlphaChem Pharmaceuticals Ltd. can establish a robust patent barrier, discouraging generic or alternative synthesis attempts and securing a foothold in targeted therapeutic areas.
5. Regulatory and Commercial Outlook
The patent’s claim to compounds with therapeutic potential positions the patent as a key step in drug development. The synthetic approach could enable streamlined manufacturing, a substantial advantage in clinical and commercial contexts. Given increasing focus on heterocyclic bioactives, this patent aligns with global growth sectors in pharmaceuticals.
6. Key Takeaways
- Claim Clarity: CY1112868 primarily claims specific heterocyclic compounds synthesized via a particular multi-step method, with functional and therapeutic applications part of the scope.
- Patent Strength: The detailed structural formulas and method steps strengthen enforceability, although prior art in heterocyclic chemistry necessitates vigilant legal defense.
- Strategic Positioning: The patent’s claims and geographic coverage position it as a valuable asset for pharmaceutical development in targeted therapeutic fields.
- Innovation Threshold: Novel synthesis methods combined with unique substituents support patent validity, but ongoing prior art monitoring is advised.
- Market Potential: The patent underpins potential drug candidates, given the bioactivity of heterocyclic compounds, with commercial value contingent on successful clinical development.
7. FAQs
Q1: What makes CY1112868 patent unique compared to existing heterocyclic patents?
A1: Its combination of a specific synthesis route and a distinct heterocyclic core structure not disclosed or claimed in prior art, coupled with its therapeutic application claims, establishes novelty.
Q2: How broad are the claims concerning the chemical entities?
A2: The chemical claims encompass a defined class of heterocyclic compounds with variable substituents, providing a focused but significant scope for various derivatives within the core structure.
Q3: Can the synthetic method claims be circumvented by alternative synthesis routes?
A3: Yes; because the claims specify a certain sequence and conditions, alternative methods that achieve the same molecules without infringing those steps may bypass protection.
Q4: What are the strategic advantages of patenting both the compounds and the synthesis method?
A4: This dual protection limits competitors from developing similar compounds via different routes and secures exclusivity in manufacturing and therapeutic use.
Q5: Is there potential for patent infringement if a competitor develops similar heterocyclic compounds?
A5: Infringement depends on the specific structural features and synthesis methods used. If their compounds fall within the structural scope and are synthesized via the claimed method, infringement could occur.
References
[1] Cyprus patent official source.
[2] Prior art databases with heterocyclic compound syntheses (e.g., WIPO PATENTSCOPE, Espacenet).
